This collaborative research (Research) has been selected for funding by the
Malaria is one of the three major infectious diseases in the world, alongside AIDS and tuberculosis. It is an infectious disease caused by the malaria parasite, primarily prevalent in tropical and subtropical regions, and transmitted by mosquitoes (Anopheles). Reportedly, there are approximately 250 million cases of infection and 610,000 deaths worldwide each year1. Progress has been made with the introduction of two vaccines in the malaria field after decades, yet their partial efficacy, together with the increasing resistance of the parasite to existing treatments, malaria remains a considerable medical need and is globally recognized as a threat to humanity.
By signing the basic agreement for this collaborative research, the four parties will collaborate on the research and development of new malaria prevention drugs and the creation of candidate compounds.
About
About MMV
MMV is a leading product development partnership in the field of antimalarial drug research, development and delivery. Its mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and delivering new, effective and affordable antimalarial drugs. MMV's vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.
About
About
The
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contact:
Web: https://www.shionogi.com
(C) 2024 Electronic News Publishing, source